Detalles de la búsqueda
1.
An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
J Allergy Clin Immunol
; 149(5): 1683-1690.e7, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34954198
2.
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.
Hum Vaccin Immunother
; 8(10): 1425-30, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23095869
Resultados
1 -
2
de 2
1
Próxima >
>>